Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide in Type 1 Diabetes with Insulin Microsecretion
NCT03668470Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Dulaglutide Arm with Placebo Arm (2 arms). Primary endpoint: Glycated Hemoglobin at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03668470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668470.